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doi:10.1016/j.ejvs.2009.05.007Abstract Objective: To evaluate homocysteine (Hcy) levels in patients with peripheral arte-
rial disease (PAD) as compared to unaffected controls, and to review the clinical effects of
therapy aimed at lowering homocysteine in PAD patients.
Methods: MEDLINE, EMBASE and Cochrane databases were searched from 1950 to December
2007. We selected observational studies and trials that evaluated Hcy levels in patients with
PAD compared to unaffected controls. We also included trials on the effect of Hcy-lowering
therapy (folate supplementation) in PAD patients. Continuous outcomes were pooled in
a random effects meta-analysis of the weighted mean difference between comparator groups.
Results: We retrieved 33 potentially suitable articles from our search. Meta-analysis of 14 rele-
vant studies showed that Hcy was significantly elevated (pooled mean difference þ4.31 mmol l;
95% C.I. 1.71, 6.31, p< 0.0001 with significant heterogeneity) in patients with PAD compared
to controls. As all 14 studies consistently demonstrated raised plasma Hcy levels in PAD
patients, the significant heterogeneity in this meta-analysis probably arises from differences
in the degree of Hcy elevation.
The effect of folate supplementation on PAD was tested in eight clinical trials but clinically
important end points were inconsistently reported.
Conclusion: Patients with PAD have significantly higher Hcy levels than unaffected controls.
However, we did not find any robust evidence on clinically beneficial effects of folate supple-
mentation in PAD.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.(N. Khandanpour).
ty for Vascular Surgery. PublisheMore than three decades ago, McCully proposed an associ-
ation between raised plasma total homocysteine (tHcy)
levels and the development of atherosclerosis.1 This
correlation has led many groups to investigate the role of
tHcy-lowering therapy in the prevention and treatment ofd by Elsevier Ltd. All rights reserved.
214 potentially relevant reports
identified and screened
33 studies reviewed based on
full text
5: not suitable PAD or no control group
2: the data for PAD were not available
6: Hcy levels were not extractable
3: had not reported tHcy levels for PAD
    and control
3: had used non-fasting or PML tHcy
14 studies included in meta-
analysis
179 excluded by review of abstracts:
not English
no PAD outcomes reported
duplicates, case reports, no control
group
Figure 1 A flow diagram of the study selection for meta-
analysis on association of plasma tHcy levels and the risk of
development of PAD.
Homocysteine in PAD 317atherosclerosis. One of the manifestations of systemic
atherosclerosis is peripheral arterial disease (PAD),
a common condition that affects about 27 million individ-
uals in North America and Europe.2
In 1995, Boushey et al. reviewed 27 studies on Hcy and
atherosclerotic disease and performed a meta-analysis of
five studies demonstrating an association between elevated
plasma Hcy levels and PAD.3 Many new observational and
experimental studies on Hcy and PAD have since been pub-
lished. Recent clinical trials in atherosclerotic patients have
also focussed on the potentially beneficial effects of folate
supplementation in tackling raised plasma Hcy levels.
We aimed to update Boushey’s analysis by conducting
a systematic review to assess Hcy levels in patients with
PAD as compared to unaffected controls. We also looked for
trials that evaluated the beneficial effects of Hcy-lowering
therapy (folate supplementation) in such patients.
Methods
The literature was systematically reviewed and synthesised
according to the methods below.
Search strategy
The following databases were searched: MEDLINE (January
1950eDecember 2007), EMBASE (January 1974eDecember
2007) and Cochrane (January 1950eDecember 2007),
restricted to English-language articles only. The Medical
Subject Headings (MeSH terms) such as ‘intermittent claudi-
cation’, ‘peripheral vascular disease’, ‘leg’, ‘femoral artery’,
‘popliteal artery’ or ‘lowerextremity’, ‘folic acid’, ‘homofolic
acid’, ‘vitamin B complex’ and the text words ‘folic acid’ and
‘folate’ and ‘homocysteine’ were used. Additional ‘related
articles’ suggested by PubMed, reference lists of the retrieved
articles and reviews on the subject were also manually eval-
uated to identify any other relevant published articles.
Eligibility criteria
Studies were included in the observational meta-analysis of
Hcy association with PAD if the plasma Hcy levels of cases
and controls were reported, and we were able to estimate
the standard deviation.
Studieswere considered for inclusion in themeta-analysis
of controlled clinical trials if PAD patients had been treated
with single or combined therapywith folic acid, vitamin B6 or
B12 as compared to no specific intervention. Eligible trials
had to recruit PAD patients defined by ankle brachial pres-
sure index (ABPI) less than 0.9, clinical evidence of inter-
mittent claudication or clearly diminished foot pulses plus
obstruction of one major peripheral artery on angiography.
Exclusion criteria
Studies were excluded if the literature was not in English or
they did not have a control group. Previous meta-analyses
and case reports were not included in this meta-analysis.
Study selection was performed by three independent
reviewers (NKH, FJM and MPA), and any discrepancies were
resolved through discussionwith other reviewers (BJ or YKL).Data extraction and synthesis
Baseline characteristics and results from the included
studies were recorded onto a spreadsheet. We extracted
data depending on whether the main variable investigated
was Hcy levels, or if the study was focussed on the effect of
folate administration.
Where relevant, RevMan 5.014 (Nordic Cochrane Centre)
was used in a meta-analysis to calculate the pooled odds
ratio (OR) for dichotomous outcomes, and the weighted
mean difference (WMD) for continuous outcomes. Statistical
heterogeneity was assessed using the Cochran Q, and the I2
statistics. I2 values of 50% ormore indicate a substantial level
of heterogeneity. If the heterogeneity was substantial
(I2> 50%), a random effects meta-analysis was performed;
otherwise a fixed effect model was used as default.
Results
A total of 214 potentially relevant studies were retrieved
from the electronic databases.
Association of plasma tHcy with PAD
After reviewing the abstracts on the effect of Hcy on PAD,
179 of the 214 studies were deemed unsuitable. From the
studies scrutinised completely, 19 were excluded for the
following reasons (see Fig. 1):
1. Coronary, cerebral and peripheral artery diseases were
not separated (two studies).4,5
2. No report of Hcy levels for the PAD and control cohorts
(three studies).6e8
3. No suitable PAD cohort or no control group (five
studies).9e13
Table 1 Study design and baseline characteristics of observational studies on the association of hyperhomocysteinaemia a PAD
Author Country Number of participants Men n (%) Age Diabetes ellitus % Total cholesterola
(mmol/L)
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
Malinow et al.23 US 103 47 26 (55.3%) 18 (38.3%) 70.1 10.6 65.9 3.9 21 (65.6% 1 (2.1%) 5.4 1.4 6.2þ 1.1
Taylor et al.24 US 214 103 110 (51%) 53 (51.5%) 64 13.1 NR NR NR NR NR
Molgaard et al.25 Sweden 78 98 78 (100%) 98 (100%) Range:
45e69
Range:
45e69
9% 0% 5.73 1.04 5.46 0.92
Bergmark et al.26 Sweden
and Norway
58 58 29 (50%) 29 (50%) 49 Age matched NR NR NR NR
Mansoor et al.27 Sweden 65 65 35 (53.8%) 34 (52.3%) mZ 47 Age matched 7 (10.8.8 ) 1 (1.5%) m: 6.3, f: 6.6 m: 6.1, f: 5.8
MZ 50b
Cheng et al.28 Hong Kong 100 100 64 (64%) 64 (64%) 67 67 35 (35%) 9 (9%) 5.88 1.63 5.44 1.04
Valentine et al.29 US 50 45 95 (100%) 45(100%) 46 0.5 45 0.5 11 (22%) 5 (11%) 18 (36%)a 9 (20%)a
Erren et al.30 Germany 15 62 11 (73%) 56 (90.3%) 63 9 56 13 9 (60%) 9 (15%) 5 (32%)a 9 (15%)a
Bunout et al.31 Chile 32 24 22 (68.8%) 12 (50%) 69.6 11 69.6 11 0% 0% 5.62 1.21 5.6 1.2
Rassoul et al.32 Germany 85 51 85 (100%) 51 (100%) 60 11 Age matched NR NR 5.62 1.5 5.3 0.7
Stricker et al.33 Switzerland 51 51 32 (62.7%) 32 (62.7%) 68.3 68.5 18 (32.3% 0 5.64 1.04 6.26 1.19
Loncar et al.34 Germany 40 40 28 (70%) 8 (30%) 51.8 7.5 51.8 7.5 0% 0% 5.8 1.23 5.7 1.21
Darius et al.35 Germany 1230 5650 109 (19.8%) 2373 (42%) Mean age overall:
72.5 5.3
Overall n mber with
diabetes 741 (25.3%)
Overall number with lipid
disorder: 3557 (51.7%)
Bhargava et al.36 India 244 205 NR NR NR NR NR NR NR NR
m: male, f: female, NR: not reported.
a Percentages represent hypercholesterolaemia.
b Values represent median.
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Mean difference in Hcy levels
Study or Subgroup
Malinow >60 yr 1989
Taylor >60 1991
Molgaard 1992
Mansoor Females 1995
Mansoor Males 1995
Valentine 1996
Cheng 1997
Erren 1999
Bunout 2000
Rassoul 2000
Loncar 2001
Stricker 2001
Bergmark  Smokers 2003
Bergmark Nonsmoker 2003
Darius 2003
Bhargava 2007
Total (95% CI)
Heterogeneity: Tau² = 26.04; Chi² = 958.61, df = 15 (P < 0.00001); I² = 98%
Test for overall effect: Z = 3.25 (P = 0.001)
Mean
16.16
14.37
16.74
14.6
15.7
15.9
28.8
23
11.7
16.4
14.9
13.3
18.79
14.05
15.2
21.79
SD
6.94
6.89
5.45
7.4
6.78
6.36
14.9
16
7.4
5.7
5.78
5.7
8.5
8
8.1
1.4
Total
29
214
78
30
35
50
100
15
32
85
40
51
31
27
1230
244
2291
Mean
10.1
10.1
13.8
11.2
11.7
14.7
20.3
17
9.3
9.7
11.32
12.6
12.85
11.79
13.9
11.33
SD
2.16
2.16
3.21
3.4
2.83
4.7
11.3
5
4.5
4.4
2.95
4.9
3.3
3.2
5.7
2.58
Total
47
29
98
31
34
45
100
62
24
51
40
51
19
39
5650
205
6525
Weight
6.3%
6.7%
6.6%
6.2%
6.4%
6.4%
6.0%
4.0%
6.1%
6.6%
6.5%
6.5%
6.1%
6.1%
6.7%
6.7%
100.0%
IV, Random, 95% CI
6.06 [3.46, 8.66]
4.27 [3.06, 5.48]
2.94 [1.57, 4.31]
3.40 [0.49, 6.31]
4.00 [1.56, 6.44]
1.20 [-1.03, 3.43]
8.50 [4.83, 12.17]
6.00 [-2.19, 14.19]
2.40 [-0.73, 5.53]
6.70 [4.99, 8.41]
3.58 [1.57, 5.59]
0.70 [-1.36, 2.76]
5.94 [2.60, 9.28]
2.26 [-0.92, 5.44]
1.30 [0.82, 1.78]
10.46 [10.07, 10.85]
4.31 [1.71, 6.91]
Cases Control Mean Difference Mean Difference
IV, Random, 95% CI
-20 -10 0 10 20
Lower Hcy in cases Raised Hcy in cases
Figure 2 Meta-analysis of observational studies on association of Hcy levels and PAD. Mean plasma tHcy for PAD in individuals was
compared with healthy individuals. A random effects (inverse variance) model was used to calculate the summary mean difference.
Homocysteine in PAD 3194. Hcy levels were not extractable for meta-analysis (six
studies).14e19
5. Used non-fasting or post-methionine loading Hcy levels
(three studies).20e22
Table 1 summarises the study design and baseline char-
acteristics of the studies included. Fourteen studies were
analysed using a random effects meta-analysis (Fig. 2).
This meta-analysis of more than 3000 patients in 14
cross-sectional and prospective studies showed that
patients with PAD had, on average, Hcy levels that were
4.31 mmol l1 higher than those of controls without PAD.
The elevated Hcy levels were a consistent finding in all 14
studies, although the magnitude or size of the difference
varied considerably, ranging from an increase of 0.70 up to
10.46 compared to controls. This diversity most likely
accounts for the significant heterogeneity amongst the
studies, with the Cochran Q of P< 0.001, and I2 of 98%
despite the direction of effect being entirely consistent.
Thus, a random effects model was used to incorporate
inter-study variation, and arrived at an ‘average’ estimate
of effect, rather than the single ‘true’ estimate obtained
with the fixed effects model. Removing any single study
from the meta-analysis did not substantially alter the
direction or magnitude of the summary statistic.
Clinical trials assessing the effect of Hcy-lowering
therapy (folate supplementation) on PAD
Owing to the diverse outcomes reported, we were unable
to conduct a meta-analysis on major clinical end points
such as the need for amputation.
There were a few studies which have used progression of
PAD as a major end point. Table 2 summarises the study
design, characteristics and outcomes of these studies. One
randomised controlled trial (RCT) assessed the effect of
150 mg folic acid day1 on patients with PAD.39 After12 months intervention, the mean ABPI in these patients
improved from 0.47 to 0.53. Pain-free walking distance,
which was measured by using treadmill set at 3 km h1 and
10% slope, also improved by 280 m. Patients’ walking
distance before the onset of claudication increased in the
intervention group (p< 0.001); ABPI also increased
(p< 0.05). In this study, however, other nutritional
supplements were also used and none of the patients was
prescribed a statin. A similar 6-week intervention study did
not demonstrate any improvement in ABPI.40
‘‘One study on PAD patients has reported a positive
correlation between the inflammatory marker and hs-CRP
(hs-CRP, highly sensitive C reactive protein)’’.42 The results
of two further clinical trials on the effect of folate on
cardiovascular markers such as CRP, inflammatory media-
tors and cholesterol profiles were not consistent.41,42 Two
trials assessed the effect of folate supplementation on
endothelium dilation and found that folate was effective in
improving endothelium-dependent dilatation. However,
the clinical relevance of the above findings is not known.
Discussion
Our meta-analysis of 14 epidemiological studies shows that
patients with PAD had consistently higher levels of Hcy as
compared to controls. These data suggest that hyper-
homocysteinaemia may either be a marker of PAD, or be
aetiologically implicated in the development of PAD. Our
results are consistent with the findings of a multicentre
case control study that was performed in nine European
countries on patients with PAD, cerebrovascular disease
and coronary artery disease.4 The multicentre study found
that plasma Hcy concentrations greater than the 80th
percentile for control subjects were associated with an
increased risk of vascular disease, independent of all
traditional risk factors. It has also been shown that plasma
tHcy is higher in patients with multi-level PAD when
Table 2 Study design and baseline characteristics of the controlled clinical trials of folate intervention in peripheral arterial disease
Author Study design
and setting
Dose
and
duration
Participant
numbers
Men n (%) Age DM n (%) Totala
cholesterol
Fall in
plasma Hcy
% (mmol/L)
Measured outcomes
Folate Controls Folate Controls Folate Controls Folate Controls Folate Controls
Brattstro¨m
et al.43
Non-randomised
clinical trial
Sweden 1990
10 mg
for 4
weeks
37 46 21
(56.8%)
22
(48.9%)
52 6 52 7 0 0 Overall, 35.1%
had elevated
levels
52.8%
(12.2)
Plasma Hcy reduced
Dudman
et al.44
Non-randomised
clinical trial
Australia 1993
5 mg
for 2
weeks
11 31 9
(50%)
20
(64.5%)
Male:
43.6 12.5;
female:
36.5
13.9
Male: (34.6
14.5);
female:
premenopause
28.8 8.1;
post-menopause:
59.1 8.3
NR NR NR NR 49% Plasma Hcy reduced
Woo et al.37 Double blind/RCT
Hong Kong 1999
10 mg
for 8
weeks
17 17 15
(88%)
15
(88%)
54 10 54 10 0 0 5.7
0.8
5.4
1.0
17.3%
(1.7)
Endothelium-dependent
dilatation of vessels: 2.5% rise.
Oral GTN dependent dilation
of vessels: 0.2% increase
Mayer
et al.38,c
Non-randomised
clinical trial
Czech 2002
5e10
mg for
3 months
33 26 19
(57.6%)
5
(19.2%)
64.8 3.1 67.3 4.4 6
(18.2%)
0 6.29 NR 25.1%
(5.8)
Plasma Hcy reduced
Sydow
et al.40
Double blind/RCT
Germany 2003
10 mg
for 8
weeks
9 9 7
(77.8%)
7
(77.8%)
69.3 68.8 1
(11.1%)
1
(11.1%)
5.9 5.8 44.9%
(7.1)
ABPI unchanged. Endothelium-
dependent dilation of vessels:
0.5% change. Oral GTN
dependent dilation of vessels:
1% decrease.
Carrero
et al.39
Double blind/RCT
Spain 2005
150 mg
for 12
months
30 30 30
(100%)
30
(100%)
62.4 1.6 65.6 1.7 5
(16%)
6
(20%)
5.43 5.42 15%
(2.61)b
ABPI increased from 0.46 0.13
to 0.53 0.13. Pain-free
walking distance improved
from 52.7 to 316.17
Ziegler
et al.41
Double blind/RCT
Austria 2005
5 mg for
6 weeks
27 22 34
(69.3%)
18
(66.7%)
68 7 69 8 9
(33%)
9
(40.9%)
4.7
0.83
158
77
34.2%
(6.95)
Plasma Hcy reduced.
ADMA, hs-CRP, triglycerides,
TC and HDL change
Schernthaner
et al.42
Double blind/RCT
Austria 2006
5 mg for
6 weeks
33 32 24
(72.7%)
22
(68.8%)
68.6 7.6 68 8.1 16
(51.5%)
16
(50%)
5.2
1.2
5.2
1.3
33%
(6.3)
Changes in hs-CRP, IL-6,
IL-8, IL-18, MCP-1, TFPI,
TF and fibrinogen
n: number, DM: diabetes mellitus.
a Percentages represent the prevalence of hypercholesterolaemia.
b Values represent total participants.
c Values represent median.
Homocysteine in PAD 321compared with subjects with either suprainguinal or
infrainguinal disease alone.26 In addition, people with
hyperhomocysteinaemia develop PAD at an earlier age.45
Plasma levels of Hcy are influenced by several factors such
as underlying genetic factors, as well as by plasma folate
and vitamin B12 levels. This may explain why vascular patients
may not always have very high plasma levels of Hcy.
Although we found inconsistent evidence for folate
supplementation in PAD, other meta-analyses have exam-
ined the effect of folic acid on coronary and cerebral artery
diseases. Wang et al. performed a meta-analysis of folic
acid supplementation on 16 841 participants from eight
clinical trials and concluded that folic acid supplementa-
tion reduced the risk of stroke by 18%.46 A similar meta-
analysis, however, reported that the overall effect of folic
acid supplementation on coronary artery disease was not
significant.47 This discrepancy might be attributed to the
arterial site. In addition, it has been suggested that folate
therapy may have a marked beneficial effect as a primary
rather than as a secondary intervention.47
Our study has some limitations. Firstly, there was
substantial heterogeneity amongst the studies, probably
because of differences in the magnitude of excess Hcy
values rather than any variation in the direction of effect as
all the studies reported a consistent association between
elevated plasma Hcy concentrations and the risk of PAD.
Eleven of the included studies in the meta-analysis showed
that hyperhomocysteinaemia had a significant association
with an increased risk of developing PAD.
Although we have used a broad search strategy, we
have only been able to analyse English studies, and it is
possible that we may have missed other studies where
authors have not fully reported their findings in published
articles. However, all 14 studies in our review have shown
a consistent effect (with a highly significant p-value of
<0.001 and lower limit of 95% confidence interval to be
1.71) and our meta-analysis is based on 8800 patients. It
would take several large studies with differing findings to
change the results of our meta-analysis.
In comparison to observational data, controlled trials are
a more reliable form of scientific evidence since they mini-
mise spurious causality and bias. However, we were unable
to identify any well-designed trials suitable for a meta-
analysis of the clinical effects of Hcy-lowering therapy. It
remains to be verified whether folate intervention would be
beneficial in patients with less severe established athero-
sclerosis andwithout end organ damage, such as renal failure
and myocardial infarction. While more than 20 000 patients
have been studied in clinical trials of the effect of Hcy-
lowering therapy on coronary and cerebral artery diseases,
only 290 patients with PAD have been investigated using
important clinical outcomes. A double-blind RCT, assessing
the outcomes of folic acid supplementation on clinical signs
of PAD, has recently been performed in our centre that may
improve our understanding of the role of folate supplemen-
tation on PAD.
In conclusion, evidence from our meta-analysis confirms
the hypothesis that patients with PAD have significantly
higher levels of Hcy. However, we also conclude that there
is little published evidence about the effects of folate
supplementation on major clinical outcomes relating to
PAD.Conflict of Interest
None declared.References
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